Skip to content

Effect of Bupivacaine in Ultrasound-guided Erector Spinae Plane

Effect of Two Different Volumes of Bupivacaine 0.25% Used in Ultrasound-guided Erector Spinae Plane (ESP) Block on Dermatome Spread: A Volume Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03650335
Enrollment
50
Registered
2018-08-28
Start date
2019-02-15
Completion date
2019-12-20
Last updated
2019-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thoracotomy

Keywords

erector spine plan block, postoperative opioid consumption, thoracotomy, analgesia, anesthesia

Brief summary

To investigate the effect of two different volumes of bupivacaine 0.25% used in ultrasound-guided erector spinae plane (ESP) block on dermatome spread and postoperative analgesia in patients undergoing unilateral thoracotomy

Detailed description

The study will have a double-blind design and will be conducted after obtaining an approval from the local ethics committee. The study will include 50 patients planned for thoracotomy, aged 18-65 years with an ASA score of I-II. The patients will be randomized by sealed tender and will be divided into 2 groups with 25 patients each. Patients that will be transferred to the intensive care unit (ICU) intubated after the surgery, patients with a body mass index of 35 or over, patients detected with infection in the intervention site, patients with hematological diseases, patients with a known allergy to local anesthetics, patients that will not provide a written or verbal consent, pregnant patients, and patients with an ASA score of III or IV will be excluded from the study. All the patients will undergo physical examination and their laboratory parameters will be evaluated one day prior to the procedure. Moreover, on the same day, each patient will be informed about dermatome testing (hot/cold), pain prick test (pain test), and pain pump set. Age, body height and weight, duration of block, and duration of surgery will be recorded for each patient

Interventions

None listed

Sponsors

Yuzuncu Yil University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years

Inclusion criteria

* Patients scheduled for elective thoracotomy * Aged 18-65 years * ASA score of I and II

Exclusion criteria

* Patients that will be transferred to the intensive care unit (ICU) intubated after the surgery, * Patients with a body mass index of 35 or over, * Patients detected with infection in the intervention site, * Patients with hematological diseases, * Patients with a known allergy to local anesthetics, * Patients that will not provide a written or verbal consent, * Pregnant patients * Patients with an ASA score of III or IV will be excluded from the study

Design outcomes

Primary

MeasureTime frameDescription
postoperative opioid consumptionFirst 24 hours total opioid consumptionTotal opioid consumption as microgram/kg will be assessed in 24 hour surgery

Countries

Turkey (Türkiye)

Contacts

Primary ContactCelaleddin Soyalp
c.soyalp@hotmail.com+905068456504
Backup ContactNureddin Yuzkat
nyuzkat@gmail.com+905052294728

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026